70 related articles for article (PubMed ID: 22314198)
1. Total and bone-specific alkaline phosphatases in haemodialysis patients with chronic liver disease.
Jean G; Souberbielle JC; Zaoui E; Lorriaux C; Mayor B; Hurot JM; Deleaval P; Chazot C
Clin Biochem; 2012 Apr; 45(6):436-9. PubMed ID: 22314198
[TBL] [Abstract][Full Text] [Related]
2. [Bone biomarkers in haemodialysis patients: bone alkaline phosphatase or ß-Crosslaps?].
Jean G; Souberbielle JC; Granjon S; Lorriaux C; Hurot JM; Mayor B; Deleaval P; Chazot C
Nephrol Ther; 2013 Jun; 9(3):154-9. PubMed ID: 23545236
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease.
Garnero P; Delmas PD
J Clin Endocrinol Metab; 1993 Oct; 77(4):1046-53. PubMed ID: 8104954
[TBL] [Abstract][Full Text] [Related]
4. Parathormone and bone-specific alkaline phosphatase for the follow-up of bone turnover in hemodialysis patients: is it so simple?
Delanaye P; Dubois BE; Jouret F; Krzesinski JM; Moranne O; Cavalier E
Clin Chim Acta; 2013 Feb; 417():35-8. PubMed ID: 23262367
[TBL] [Abstract][Full Text] [Related]
5. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients.
Couttenye MM; D'Haese PC; Van Hoof VO; Lemoniatou E; Goodman W; Verpooten GA; De Broe ME
Nephrol Dial Transplant; 1996 Jun; 11(6):1065-72. PubMed ID: 8671970
[TBL] [Abstract][Full Text] [Related]
6. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH.
Ueda M; Inaba M; Okuno S; Maeno Y; Ishimura E; Yamakawa T; Nishizawa Y
Life Sci; 2005 Jul; 77(10):1130-9. PubMed ID: 15978265
[TBL] [Abstract][Full Text] [Related]
7. Association between phosphate removal and markers of bone turnover in haemodialysis patients.
Albalate M; de la Piedra C; Fernández C; Lefort M; Santana H; Hernando P; Hernández J; Caramelo C
Nephrol Dial Transplant; 2006 Jun; 21(6):1626-32. PubMed ID: 16490746
[TBL] [Abstract][Full Text] [Related]
8. Correlation between parathyroid hormone, bone alkaline phosphatase and N-telopeptide of type 1 collagen in diabetic and non-diabetic haemodialysis patients.
Takahashi N; Kojima T; Ogawa H; Ishiguro N
Nephrology (Carlton); 2007 Dec; 12(6):539-45. PubMed ID: 17995578
[TBL] [Abstract][Full Text] [Related]
9. The source and clinical significance of serum alkaline phosphatases in patients treated by chronic dialysis.
Stĕpán J; Pilarová T; Melicharová D
Acta Univ Carol Med Monogr; 1977; (78 Pt 2):75-9. PubMed ID: 615470
[TBL] [Abstract][Full Text] [Related]
10. Correlation of bone alkaline phosphatase and iPTH with some basic biochemical markers in predialysis and dialysis patients.
Milinković NL; Majkic-Singh NT; Ignjatović SD; Lezaić VD; Pejanović SD; Jovanovic DB
Clin Lab; 2012; 58(7-8):747-53. PubMed ID: 22997975
[TBL] [Abstract][Full Text] [Related]
11. Association between very low PTH levels and poor survival rates in haemodialysis patients: results from the French ARNOS cohort.
Jean G; Lataillade D; Genet L; Legrand E; Kuentz F; Moreau-Gaudry X; Fouque D;
Nephron Clin Pract; 2011; 118(2):c211-6. PubMed ID: 21178378
[TBL] [Abstract][Full Text] [Related]
12. [Clinical evaluation of the results of the Sr85 test and of bone alkaline phosphatase isoenzyme activity].
Stĕpán J; Kolár J; Stĕpán J; Susta A
Z Rheumatol; 1977; 36(3-4):120-5. PubMed ID: 871069
[TBL] [Abstract][Full Text] [Related]
13. Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus.
Inaba M; Nagasue K; Okuno S; Ueda M; Kumeda Y; Imanishi Y; Shoji T; Ishimura E; Ohta T; Nakatani T; Kim M; Nishizawa Y
Am J Kidney Dis; 2002 Jun; 39(6):1261-9. PubMed ID: 12046040
[TBL] [Abstract][Full Text] [Related]
14. [The relationship between bone mineral density and secondary hyperparathyroidism bone disease].
Ning JP; Sun M; Toru I; Etsuo Y
Hunan Yi Ke Da Xue Xue Bao; 2000 Feb; 25(1):77-9. PubMed ID: 12212259
[TBL] [Abstract][Full Text] [Related]
15. [Serum osteocalcin in children with chronic renal insufficiency].
Peco-Antić A; Nastić-Mirić D; Milikić V; Babić D; Pejcić I; Kostić M; Paripović V; Jovanović O; Kruscić D; Mancić J
Srp Arh Celok Lek; 1996; 124(9-10):227-31. PubMed ID: 9102853
[TBL] [Abstract][Full Text] [Related]
16. Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease.
Grzegorzewska AE; Młot M
Rocz Akad Med Bialymst; 2004; 49():190-2. PubMed ID: 15631341
[TBL] [Abstract][Full Text] [Related]
17. Effects of vitamin K2 in hemodialysis patients with low serum parathyroid hormone levels.
Nakashima A; Yorioka N; Doi S; Masaki T; Ito T; Harada S
Bone; 2004 Mar; 34(3):579-83. PubMed ID: 15003806
[TBL] [Abstract][Full Text] [Related]
18. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
[TBL] [Abstract][Full Text] [Related]
19. Calcitropic hormonal status in north Indian patients with end-stage renal disease.
Singh AK; Avula S; Kher V; Rao DS; Mithal A
Natl Med J India; 1999; 12(5):202-7. PubMed ID: 10612998
[TBL] [Abstract][Full Text] [Related]
20. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
Nasri H; Baradaran A; Naderi AS
Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
